NASDAQ:ADPT Adaptive Biotechnologies (ADPT) Stock Price, News & Analysis $15.15 -0.04 (-0.26%) Closing price 04:00 PM EasternExtended Trading$13.90 -1.25 (-8.25%) As of 05:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Adaptive Biotechnologies Stock (NASDAQ:ADPT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ADPT alerts:Sign Up Key Stats Today's Range$15.10▼$15.5950-Day Range$12.41▼$15.1952-Week Range$9.05▼$20.76Volume2.29 million shsAverage Volume1.92 million shsMarket Capitalization$2.42 billionP/E RatioN/ADividend YieldN/APrice Target$19.57Consensus RatingModerate Buy Company Overview Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development. The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners. Adaptive also develops T-cell receptor (TCR) discovery services to support the discovery and development of novel TCR-based therapeutics. Its offerings span research services, clinical diagnostics, and collaborative programs with leading drug developers to advance immune-driven medicine. Founded in 2009 and headquartered in Seattle, Washington, Adaptive Biotechnologies maintains research and operations facilities in North America and Europe. The company collaborates with global technology and life sciences organizations, including a strategic partnership with Microsoft to apply machine learning to immune data. Adaptive’s platform has been utilized in oncology, autoimmune and infectious disease research across multiple continents. Adaptive Biotechnologies is led by co-founder and CEO Chad Robins, under whose guidance the firm continues to expand its molecular profiling capabilities and build a world-class immune medicine business.AI Generated. May Contain Errors. Read More Adaptive Biotechnologies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreADPT MarketRank™: Adaptive Biotechnologies scored higher than 69% of companies evaluated by MarketBeat, and ranked 281st out of 871 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingAdaptive Biotechnologies has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAdaptive Biotechnologies has a consensus price target of $19.57, representing about 28.4% upside from its current price of $15.24.Amount of Analyst CoverageAdaptive Biotechnologies has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Adaptive Biotechnologies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($0.48) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptive Biotechnologies is -46.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptive Biotechnologies is -46.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptive Biotechnologies has a P/B Ratio of 10.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Adaptive Biotechnologies' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.90% of the float of Adaptive Biotechnologies has been sold short.Short Interest Ratio / Days to CoverAdaptive Biotechnologies has a short interest ratio ("days to cover") of 4.55.Change versus previous monthShort interest in Adaptive Biotechnologies has recently increased by 5.42%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdaptive Biotechnologies does not currently pay a dividend.Dividend GrowthAdaptive Biotechnologies does not have a long track record of dividend growth. News and Social Media4.0 / 5News Sentiment1.41 News SentimentAdaptive Biotechnologies has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Adaptive Biotechnologies this week, compared to 5 articles on an average week.Search Interest3 people have searched for ADPT on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Adaptive Biotechnologies to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $31,269,192.00 in company stock.Percentage Held by Insiders5.70% of the stock of Adaptive Biotechnologies is held by insiders.Percentage Held by Institutions99.17% of the stock of Adaptive Biotechnologies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Adaptive Biotechnologies' insider trading history. Receive ADPT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptive Biotechnologies and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADPT Stock News HeadlinesAdaptive Biotechnologies Announces Extensive Presence at ASCO and EHA Conferences Showcasing clonoSEQ Test for MRD AssessmentMay 29 at 7:50 AM | quiverquant.comQAt ASCO and EHA 2026, New Data Reinforce the Pivotal Role of clonoSEQ® MRD Testing Across Hematology Clinical Practice and ResearchMay 29 at 7:30 AM | globenewswire.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 29 at 1:00 AM | Profits Run (Ad)Adaptive Biotechnologies to Participate in Upcoming Investor ConferencesMay 21, 2026 | markets.businessinsider.comAdaptive Biotechnologies to Participate in Upcoming Investor ConferencesMay 21, 2026 | globenewswire.comAdaptive Biotechnologies (NASDAQ:ADPT) CFO Sells $40,619.60 in StockMay 21, 2026 | insidertrades.comAdaptive Biotechnologies Corp.May 20, 2026 | edition.cnn.comAdaptive Biotechnologies (NASDAQ:ADPT) COO Sells $270,896.51 in StockApril 30, 2026 | insidertrades.comSee More Headlines ADPT Stock Analysis - Frequently Asked Questions How have ADPT shares performed this year? Adaptive Biotechnologies' stock was trading at $16.24 at the start of the year. Since then, ADPT shares have decreased by 6.2% and is now trading at $15.2380. How were Adaptive Biotechnologies' earnings last quarter? Adaptive Biotechnologies Corporation (NASDAQ:ADPT) issued its earnings results on Tuesday, May, 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.16) by $0.03. The firm's revenue was up 35.1% compared to the same quarter last year. Read the conference call transcript. When did Adaptive Biotechnologies IPO? Adaptive Biotechnologies (ADPT) raised $278 million in an IPO on Thursday, June 27th 2019. The company issued 15,000,000 shares at $18.00-$19.00 per share. Goldman Sachs, J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Guggenheim Securities, William Blair and BTIG were co-managers. Who are Adaptive Biotechnologies' major shareholders? Top institutional shareholders of Adaptive Biotechnologies include Arrowstreet Capital Limited Partnership (1.25%), Aristotle Atlantic Partners LLC (1.07%), Principal Financial Group Inc. (1.07%) and Sumitomo Mitsui Trust Group Inc. (1.04%). Insiders that own company stock include Chad M Robins, Harlan S Robins, Tycho Peterson, Susan Bobulsky, Julie Rubinstein, Sharon Benzeno, Francis Lo, Kyle Piskel, Nitin Sood, Peter M Neupert, Stacy L Taylor, Michelle Renee Griffin and Robert Hershberg. View institutional ownership trends. How do I buy shares of Adaptive Biotechnologies? Shares of ADPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adaptive Biotechnologies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptive Biotechnologies investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings5/05/2026Today5/29/202646th Annual William Blair Growth Stock Conference6/03/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 9 days, ADPT's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADPT CIK1478320 Webwww.constructionpartners.net Phone(206) 659-0067Fax206-659-0667Employees790Year Founded2009Price Target and Rating Average Price Target for Adaptive Biotechnologies$19.57 High Price Target$22.00 Low Price Target$15.00 Potential Upside/Downside+29.2%Consensus RatingModerate Buy Rating Score (0-4)2.63 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$59.50 million Net Margins-16.82% Pretax Margin-16.81% Return on Equity-40.06% Return on Assets-16.64% Debt Debt-to-Equity RatioN/A Current Ratio3.35 Quick Ratio3.22 Sales & Book Value Annual Sales$276.98 million Price / Sales8.75 Cash FlowN/A Price / Cash FlowN/A Book Value$1.40 per share Price / Book10.82Miscellaneous Outstanding Shares160,040,000Free Float150,921,000Market Cap$2.42 billion OptionableOptionable Beta2.16 Social Links Don't wait for the SpaceX IPOThe space race is growing fast, and you don’t have to wait for SpaceX to go public to invest. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:ADPT) was last updated on 5/29/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
